GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery
Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Activin receptor-like kinase 2) (ALK-2) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I)
ACVR1_HUMAN Reviewed; 509 AA.
Q04771;
01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
01-FEB-1994, sequence version 1.
28-MAR-2018, entry version 185.
RecName: Full=Activin receptor type-1;
EC=2.7.11.30;
AltName: Full=Activin receptor type I;
Short=ACTR-I;
AltName: Full=Activin receptor-like kinase 2;
Short=ALK-2;
AltName: Full=Serine/threonine-protein kinase receptor R1;
Short=SKR1;
AltName: Full=TGF-B superfamily receptor type I;
Short=TSR-I;
Flags: Precursor;
Name=ACVR1; Synonyms=ACVRLK2;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=8389764;
Matsuzaki K., McKeehan W.L.;
"A widely expressed transmembrane serine/threonine kinase that does
not bind activin, inhibin, transforming growth factor beta, or bone
morphogenic factor.";
J. Biol. Chem. 268:12719-12723(1993).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
TISSUE=Placenta;
PubMed=8397373;
ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
Toyoshima H., Heldin C.-H., Miyazono K.;
"Activin receptor-like kinases: a novel subclass of cell-surface
receptors with predicted serine/threonine kinase activity.";
Oncogene 8:2879-2887(1993).
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Lung;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[4]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION
BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
Mann M., Daub H.;
"Large-scale proteomics analysis of the human kinome.";
Mol. Cell. Proteomics 8:1751-1764(2009).
[5]
INTERACTION WITH FCHO1.
PubMed=22484487; DOI=10.1038/ncb2473;
Umasankar P.K., Sanker S., Thieman J.R., Chakraborty S., Wendland B.,
Tsang M., Traub L.M.;
"Distinct and separable activities of the endocytic clathrin-coat
components Fcho1/2 and AP-2 in developmental patterning.";
Nat. Cell Biol. 14:488-501(2012).
[6]
X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 172-499 IN COMPLEX WITH
FKBP1A.
Structural genomics consortium (SGC);
"Crystal structure of the kinase domain of type I activin receptor
(ACVR1) in complex with FKBP12 and dorsomorphin.";
Submitted (JUN-2009) to the PDB data bank.
[7]
VARIANT FOP HIS-206.
PubMed=16642017; DOI=10.1038/ng1783;
Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Brown M.A.,
Kaplan F.S.;
"A recurrent mutation in the BMP type I receptor ACVR1 causes
inherited and sporadic fibrodysplasia ossificans progressiva.";
Nat. Genet. 38:525-527(2006).
[8]
VARIANTS [LARGE SCALE ANALYSIS] GLY-15; PHE-41; GLN-47 AND SER-115.
PubMed=17344846; DOI=10.1038/nature05610;
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
"Patterns of somatic mutation in human cancer genomes.";
Nature 446:153-158(2007).
[9]
VARIANTS FOP 197-PRO-PHE-198 DELINS LEU; HIS-206; GLU-207; ARG-328;
TRP-328; GLU-328; ASP-356 AND PRO-375.
PubMed=19085907; DOI=10.1002/humu.20868;
Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L.,
Delai P., Fastnacht-Urban E., Forman S.J., Gillessen-Kaesbach G.,
Hoover-Fong J., Koester B., Pauli R.M., Reardon W., Zaidi S.A.,
Zasloff M., Morhart R., Mundlos S., Groppe J., Shore E.M.;
"Classic and atypical fibrodysplasia ossificans progressiva (FOP)
phenotypes are caused by mutations in the bone morphogenetic protein
(BMP) type I receptor ACVR1.";
Hum. Mutat. 30:379-390(2009).
[10]
VARIANTS FOP ILE-202 AND GLU-328.
PubMed=19330033; DOI=10.1371/journal.pone.0005005;
Petrie K.A., Lee W.H., Bullock A.N., Pointon J.J., Smith R.,
Russell R.G., Brown M.A., Wordsworth B.P., Triffitt J.T.;
"Novel mutations in ACVR1 result in atypical features in two
fibrodysplasia ossificans progressiva patients.";
PLoS ONE 4:E5005-E5005(2009).
-!- FUNCTION: On ligand binding, forms a receptor complex consisting
of two type II and two type I transmembrane serine/threonine
kinases. Type II receptors phosphorylate and activate type I
receptors which autophosphorylate, then bind and activate SMAD
transcriptional regulators. Receptor for activin. May be involved
for left-right pattern formation during embryogenesis (By
similarity). {ECO:0000250}.
-!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
protein] phosphate.
-!- COFACTOR:
Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
-!- SUBUNIT: Interacts with FKBP1A. Interacts with FCHO1.
{ECO:0000269|PubMed:22484487, ECO:0000269|Ref.6}.
-!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
protein.
-!- TISSUE SPECIFICITY: Expressed in normal parenchymal cells,
endothelial cells, fibroblasts and tumor-derived epithelial cells.
-!- DISEASE: Fibrodysplasia ossificans progressiva (FOP) [MIM:135100]:
A rare autosomal dominant connective tissue disorder resulting in
skeletal malformations and progressive extraskeletal ossification.
Heterotopic ossification begins in childhood and can be induced by
trauma or may occur without warning. Bone formation is episodic
and progressive, leading to a debilitating ankylosis of all major
joints of the axial and appendicular skeleton, rendering movement
impossible. {ECO:0000269|PubMed:16642017,
ECO:0000269|PubMed:19085907, ECO:0000269|PubMed:19330033}.
Note=The disease is caused by mutations affecting the gene
represented in this entry.
-!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; L02911; AAA36614.1; -; mRNA.
EMBL; Z22534; CAA80256.1; -; mRNA.
EMBL; BC033867; AAH33867.1; -; mRNA.
CCDS; CCDS2206.1; -.
PIR; A45992; A45992.
RefSeq; NP_001096.1; NM_001105.4.
RefSeq; NP_001104537.1; NM_001111067.2.
RefSeq; NP_001334592.1; NM_001347663.1.
RefSeq; NP_001334593.1; NM_001347664.1.
RefSeq; NP_001334594.1; NM_001347665.1.
RefSeq; NP_001334595.1; NM_001347666.1.
RefSeq; NP_001334596.1; NM_001347667.1.
RefSeq; XP_006712888.1; XM_006712825.3.
RefSeq; XP_011510410.1; XM_011512108.2.
UniGene; Hs.470316; -.
PDB; 3H9R; X-ray; 2.35 A; A=172-499.
PDB; 3MTF; X-ray; 2.15 A; A/B=201-499.
PDB; 3OOM; X-ray; 2.00 A; A=201-499.
PDB; 3Q4U; X-ray; 1.82 A; A/B/C/D=201-499.
PDB; 4BGG; X-ray; 2.56 A; A/B/C/D=201-499.
PDB; 4C02; X-ray; 2.17 A; A=172-499.
PDB; 4DYM; X-ray; 2.42 A; A=201-499.
PDB; 5OXG; X-ray; 2.13 A; A/B/C/D=201-499.
PDB; 5OY6; X-ray; 2.56 A; A/B/C/D=201-499.
PDB; 6EIX; X-ray; 2.30 A; A=172-509.
PDBsum; 3H9R; -.
PDBsum; 3MTF; -.
PDBsum; 3OOM; -.
PDBsum; 3Q4U; -.
PDBsum; 4BGG; -.
PDBsum; 4C02; -.
PDBsum; 4DYM; -.
PDBsum; 5OXG; -.
PDBsum; 5OY6; -.
PDBsum; 6EIX; -.
ProteinModelPortal; Q04771; -.
SMR; Q04771; -.
BioGrid; 106605; 71.
DIP; DIP-212N; -.
IntAct; Q04771; 14.
MINT; Q04771; -.
STRING; 9606.ENSP00000263640; -.
BindingDB; Q04771; -.
ChEMBL; CHEMBL5903; -.
DrugBank; DB00171; Adenosine triphosphate.
GuidetoPHARMACOLOGY; 1785; -.
iPTMnet; Q04771; -.
PhosphoSitePlus; Q04771; -.
BioMuta; ACVR1; -.
DMDM; 462447; -.
EPD; Q04771; -.
MaxQB; Q04771; -.
PaxDb; Q04771; -.
PeptideAtlas; Q04771; -.
PRIDE; Q04771; -.
DNASU; 90; -.
Ensembl; ENST00000263640; ENSP00000263640; ENSG00000115170.
Ensembl; ENST00000409283; ENSP00000387273; ENSG00000115170.
Ensembl; ENST00000410057; ENSP00000387127; ENSG00000115170.
Ensembl; ENST00000434821; ENSP00000405004; ENSG00000115170.
GeneID; 90; -.
KEGG; hsa:90; -.
UCSC; uc002tzm.4; human.
CTD; 90; -.
DisGeNET; 90; -.
EuPathDB; HostDB:ENSG00000115170.13; -.
GeneCards; ACVR1; -.
HGNC; HGNC:171; ACVR1.
HPA; HPA007505; -.
MalaCards; ACVR1; -.
MIM; 102576; gene.
MIM; 135100; phenotype.
neXtProt; NX_Q04771; -.
OpenTargets; ENSG00000115170; -.
Orphanet; 337; Fibrodysplasia ossificans progressiva.
PharmGKB; PA24492; -.
eggNOG; KOG2052; Eukaryota.
eggNOG; ENOG410XQT0; LUCA.
GeneTree; ENSGT00760000118876; -.
HOGENOM; HOG000230587; -.
HOVERGEN; HBG054502; -.
InParanoid; Q04771; -.
KO; K04675; -.
OMA; GHLCNMN; -.
OrthoDB; EOG091G0BIU; -.
PhylomeDB; Q04771; -.
TreeFam; TF314724; -.
BRENDA; 2.7.10.2; 2681.
SignaLink; Q04771; -.
SIGNOR; Q04771; -.
ChiTaRS; ACVR1; human.
EvolutionaryTrace; Q04771; -.
GeneWiki; ACVR1; -.
GenomeRNAi; 90; -.
PRO; PR:Q04771; -.
Proteomes; UP000005640; Chromosome 2.
Bgee; ENSG00000115170; -.
CleanEx; HS_ACVR1; -.
ExpressionAtlas; Q04771; baseline and differential.
Genevisible; Q04771; HS.
GO; GO:0048179; C:activin receptor complex; IDA:UniProtKB.
GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
GO; GO:0048185; F:activin binding; IDA:UniProtKB.
GO; GO:0016361; F:activin receptor activity, type I; IEA:Ensembl.
GO; GO:0005524; F:ATP binding; IDA:HGNC.
GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
GO; GO:0017046; F:peptide hormone binding; NAS:UniProtKB.
GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
GO; GO:0046332; F:SMAD binding; IDA:HGNC.
GO; GO:0050431; F:transforming growth factor beta binding; IDA:UniProtKB.
GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IEA:Ensembl.
GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB.
GO; GO:0032924; P:activin receptor signaling pathway; IDA:BHF-UCL.
GO; GO:0002526; P:acute inflammatory response; IEA:Ensembl.
GO; GO:0003289; P:atrial septum primum morphogenesis; IMP:BHF-UCL.
GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL.
GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
GO; GO:0061312; P:BMP signaling pathway involved in heart development; ISS:BHF-UCL.
GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl.
GO; GO:0060923; P:cardiac muscle cell fate commitment; IMP:BHF-UCL.
GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl.
GO; GO:0003143; P:embryonic heart tube morphogenesis; IMP:BHF-UCL.
GO; GO:0061445; P:endocardial cushion cell fate commitment; IMP:BHF-UCL.
GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL.
GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:HGNC.
GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl.
GO; GO:0007281; P:germ cell development; IEA:Ensembl.
GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
GO; GO:0003183; P:mitral valve morphogenesis; IMP:BHF-UCL.
GO; GO:0032926; P:negative regulation of activin receptor signaling pathway; IMP:HGNC.
GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
GO; GO:0009968; P:negative regulation of signal transduction; IMP:HGNC.
GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
GO; GO:0060037; P:pharyngeal system development; IEA:Ensembl.
GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
GO; GO:0030335; P:positive regulation of cell migration; IGI:BHF-UCL.
GO; GO:2000017; P:positive regulation of determination of dorsal identity; IDA:BHF-UCL.
GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
GO; GO:0030278; P:regulation of ossification; IMP:UniProtKB.
GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl.
GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
InterPro; IPR000472; Activin_recp.
InterPro; IPR003605; GS_dom.
InterPro; IPR011009; Kinase-like_dom_sf.
InterPro; IPR000719; Prot_kinase_dom.
InterPro; IPR017441; Protein_kinase_ATP_BS.
InterPro; IPR008271; Ser/Thr_kinase_AS.
InterPro; IPR000333; TGFB_receptor.
PANTHER; PTHR23255; PTHR23255; 1.
Pfam; PF01064; Activin_recp; 1.
Pfam; PF00069; Pkinase; 1.
Pfam; PF08515; TGF_beta_GS; 1.
PRINTS; PR00653; ACTIVIN2R.
SMART; SM00467; GS; 1.
SMART; SM00220; S_TKc; 1.
SUPFAM; SSF56112; SSF56112; 1.
PROSITE; PS51256; GS; 1.
PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
1: Evidence at protein level;
3D-structure; ATP-binding; Complete proteome; Disease mutation;
Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
Reference proteome; Serine/threonine-protein kinase; Signal;
Transferase; Transmembrane; Transmembrane helix.
SIGNAL 1 20 {ECO:0000250}.
CHAIN 21 509 Activin receptor type-1.
/FTId=PRO_0000024394.
TOPO_DOM 21 123 Extracellular. {ECO:0000255}.
TRANSMEM 124 146 Helical. {ECO:0000255}.
TOPO_DOM 147 509 Cytoplasmic. {ECO:0000255}.
DOMAIN 178 207 GS. {ECO:0000255|PROSITE-
ProRule:PRU00585}.
DOMAIN 208 502 Protein kinase. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
NP_BIND 214 222 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
ACT_SITE 336 336 Proton acceptor. {ECO:0000255|PROSITE-
ProRule:PRU00159, ECO:0000255|PROSITE-
ProRule:PRU10027}.
BINDING 235 235 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
MOD_RES 501 501 Phosphoserine.
{ECO:0000244|PubMed:19369195}.
CARBOHYD 102 102 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
VARIANT 15 15 A -> G (in dbSNP:rs13406336).
{ECO:0000269|PubMed:17344846}.
/FTId=VAR_041392.
VARIANT 41 41 S -> F (in dbSNP:rs55957214).
{ECO:0000269|PubMed:17344846}.
/FTId=VAR_041393.
VARIANT 47 47 H -> Q (in dbSNP:rs34056189).
{ECO:0000269|PubMed:17344846}.
/FTId=VAR_041394.
VARIANT 115 115 P -> S (in a melanoma sample; somatic
mutation). {ECO:0000269|PubMed:17344846}.
/FTId=VAR_041395.
VARIANT 197 198 PF -> L (in FOP; variant phenotype).
{ECO:0000269|PubMed:19085907}.
/FTId=VAR_058418.
VARIANT 202 202 R -> I (in FOP; with some atypical
features; dbSNP:rs387906591).
{ECO:0000269|PubMed:19330033}.
/FTId=VAR_058419.
VARIANT 206 206 R -> H (in FOP; dbSNP:rs121912678).
{ECO:0000269|PubMed:16642017,
ECO:0000269|PubMed:19085907}.
/FTId=VAR_028444.
VARIANT 207 207 Q -> E (in FOP; with some atypical
features). {ECO:0000269|PubMed:19085907}.
/FTId=VAR_058420.
VARIANT 328 328 G -> E (in FOP; variant phenotype;
dbSNP:rs387906589).
{ECO:0000269|PubMed:19085907,
ECO:0000269|PubMed:19330033}.
/FTId=VAR_058421.
VARIANT 328 328 G -> R (in FOP; variant phenotype;
dbSNP:rs387906588).
{ECO:0000269|PubMed:19085907}.
/FTId=VAR_058422.
VARIANT 328 328 G -> W (in FOP; variant phenotype;
dbSNP:rs387906588).
{ECO:0000269|PubMed:19085907}.
/FTId=VAR_058423.
VARIANT 356 356 G -> D (in FOP; variant phenotype;
dbSNP:rs121912679).
{ECO:0000269|PubMed:19085907}.
/FTId=VAR_058424.
VARIANT 375 375 R -> P (in FOP; variant phenotype;
dbSNP:rs387906590).
{ECO:0000269|PubMed:19085907}.
/FTId=VAR_058425.
HELIX 180 184 {ECO:0000244|PDB:4C02}.
STRAND 192 196 {ECO:0000244|PDB:4C02}.
HELIX 205 207 {ECO:0000244|PDB:3Q4U}.
STRAND 209 216 {ECO:0000244|PDB:3Q4U}.
STRAND 218 227 {ECO:0000244|PDB:3Q4U}.
STRAND 230 237 {ECO:0000244|PDB:3Q4U}.
HELIX 239 241 {ECO:0000244|PDB:3Q4U}.
HELIX 242 254 {ECO:0000244|PDB:3Q4U}.
STRAND 265 273 {ECO:0000244|PDB:3Q4U}.
STRAND 276 283 {ECO:0000244|PDB:3Q4U}.
HELIX 291 295 {ECO:0000244|PDB:3Q4U}.
HELIX 302 320 {ECO:0000244|PDB:3Q4U}.
STRAND 325 327 {ECO:0000244|PDB:3MTF}.
STRAND 331 333 {ECO:0000244|PDB:3Q4U}.
HELIX 339 341 {ECO:0000244|PDB:3Q4U}.
STRAND 342 344 {ECO:0000244|PDB:3Q4U}.
STRAND 350 352 {ECO:0000244|PDB:3Q4U}.
STRAND 359 362 {ECO:0000244|PDB:3Q4U}.
TURN 363 366 {ECO:0000244|PDB:3Q4U}.
STRAND 367 369 {ECO:0000244|PDB:3Q4U}.
HELIX 379 381 {ECO:0000244|PDB:3Q4U}.
HELIX 384 387 {ECO:0000244|PDB:3Q4U}.
HELIX 396 415 {ECO:0000244|PDB:3Q4U}.
TURN 430 434 {ECO:0000244|PDB:3Q4U}.
HELIX 441 448 {ECO:0000244|PDB:3Q4U}.
HELIX 459 463 {ECO:0000244|PDB:3Q4U}.
HELIX 465 477 {ECO:0000244|PDB:3Q4U}.
HELIX 482 484 {ECO:0000244|PDB:3Q4U}.
HELIX 488 498 {ECO:0000244|PDB:3Q4U}.
SEQUENCE 509 AA; 57153 MW; E2B0F051D19DD052 CRC64;
MVDGVMILPV LIMIALPSPS MEDEKPKVNP KLYMCVCEGL SCGNEDHCEG QQCFSSLSIN
DGFHVYQKGC FQVYEQGKMT CKTPPSPGQA VECCQGDWCN RNITAQLPTK GKSFPGTQNF
HLEVGLIILS VVFAVCLLAC LLGVALRKFK RRNQERLNPR DVEYGTIEGL ITTNVGDSTL
ADLLDHSCTS GSGSGLPFLV QRTVARQITL LECVGKGRYG EVWRGSWQGE NVAVKIFSSR
DEKSWFRETE LYNTVMLRHE NILGFIASDM TSRHSSTQLW LITHYHEMGS LYDYLQLTTL
DTVSCLRIVL SIASGLAHLH IEIFGTQGKP AIAHRDLKSK NILVKKNGQC CIADLGLAVM
HSQSTNQLDV GNNPRVGTKR YMAPEVLDET IQVDCFDSYK RVDIWAFGLV LWEVARRMVS
NGIVEDYKPP FYDVVPNDPS FEDMRKVVCV DQQRPNIPNR WFSDPTLTSL AKLMKECWYQ
NPSARLTALR IKKTLTKIDN SLDKLKTDC
Related products :
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Pathways :
WP2272: Pathogenic Escherichia coli infection
WP2292: Chemokine signaling pathway
WP1004: Kit Receptor Signaling Pathway
WP1011: T Cell Receptor Signaling Pathway
WP1014: Androgen receptor signaling pathway
WP1025: B Cell Receptor Signaling Pathway
WP1045: TGF-beta Receptor Signaling Pathway
WP1046: Signaling of Hepatocyte Growth Factor Receptor
WP1067: Toll-like receptor signaling pathway
WP1112: EPO Receptor Signaling
WP1121: Kit Receptor Signaling Pathway
WP1130: T Cell Receptor Signaling Pathway
WP1133: Androgen receptor signaling pathway
WP1144: B Cell Receptor Signaling Pathway
WP1161: TGF-beta Receptor Signaling Pathway
WP1162: Signaling of Hepatocyte Growth Factor Receptor
WP1183: Toll-like receptor signaling pathway
WP1206: Signaling of Hepatocyte Growth Factor Receptor
WP1235: Signaling of Hepatocyte Growth Factor Receptor
WP1249: EPO Receptor Signaling
WP1271: Toll-like receptor signaling pathway
WP1284: EPO Receptor Signaling
WP1309: Toll-like receptor signaling pathway
WP1336: EPO Receptor Signaling
WP1341: Kit Receptor Signaling Pathway
Related Genes :
[ACVR1B ACVRLK4 ALK4] Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2)
[Acvr1b Alk4] Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2)
[Acvr1b Acvrlk4 Alk4] Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2)
[ACVR1 ACVRLK2] Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Activin receptor-like kinase 2) (ALK-2) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I)
[Acvr1c Alk7] Activin receptor type-1C (EC 2.7.11.30) (Activin receptor type IC) (ACTR-IC) (Activin receptor-like kinase 7) (ALK-7)
[ACVR1C ALK7] Activin receptor type-1C (EC 2.7.11.30) (Activin receptor type IC) (ACTR-IC) (Activin receptor-like kinase 7) (ALK-7)
[Acvr1c Alk7] Activin receptor type-1C (EC 2.7.11.30) (Activin receptor type IC) (ACTR-IC) (Activin receptor-like kinase 7) (ALK-7)
[ACVR2B] Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB)
[Acvr2b] Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB)
[Acvr2b Actriib] Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB)
[ACVR2A] Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA)
[Acvr2a Acvr2] Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA)
[ACVR2B] Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB)
[ACVR2A ACVR2] Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA)
[Acvr2a Actrii Acvr2] Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA)
[Synj2bp Arip2 Omp25] Synaptojanin-2-binding protein (Activin receptor-interacting protein 2) (Activin receptor-interacting protein 4) (Mitochondrial outer membrane protein 25)
[ACVR2A ACTRII ACVR2] Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA)
[Acvr1 Acvrlk2] Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I)
[Acvr1 Acvrlk2 Tgfb1] Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I) (TSK-7L)
[ACVR1] Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (Type I TGF B receptor)
[Foxh1 Fast1 Fast2] Forkhead box protein H1 (Forkhead activin signal transducer 1) (Fast-1) (Forkhead activin signal transducer 2) (Fast-2)
[FOXH1 FAST1 FAST2] Forkhead box protein H1 (Forkhead activin signal transducer 1) (Fast-1) (hFAST-1) (Forkhead activin signal transducer 2) (Fast-2)
[ACVR1 ACVRLK2] Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Serine/threonine-protein kinase receptor R1) (SKR1)
[TGFBR1 ALK5 SKR4] TGF-beta receptor type-1 (TGFR-1) (EC 2.7.11.30) (Activin A receptor type II-like protein kinase of 53kD) (Activin receptor-like kinase 5) (ALK-5) (ALK5) (Serine/threonine-protein kinase receptor R4) (SKR4) (TGF-beta type I receptor) (Transforming growth factor-beta receptor type I) (TGF-beta receptor type I) (TbetaR-I)
[INHBA] Inhibin beta A chain (Activin beta-A chain) (Erythroid differentiation protein) (EDF)
[ACVRL1 ACVRLK1 ALK1] Serine/threonine-protein kinase receptor R3 (SKR3) (EC 2.7.11.30) (Activin receptor-like kinase 1) (ALK-1) (TGF-B superfamily receptor type I) (TSR-I)
[FST] Follistatin (FS) (Activin-binding protein)
[INHBA] Inhibin beta A chain (Activin beta-A chain)
[INHBA] Inhibin beta A chain (Activin beta-A chain)
[INHBA] Inhibin beta A chain (Activin beta-A chain)
Bibliography :
No related Items
Enter catalog number :
Favorites Pages:
No Favorits